WO1994008596A1 - Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it - Google Patents

Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it Download PDF

Info

Publication number
WO1994008596A1
WO1994008596A1 PCT/GB1993/002141 GB9302141W WO9408596A1 WO 1994008596 A1 WO1994008596 A1 WO 1994008596A1 GB 9302141 W GB9302141 W GB 9302141W WO 9408596 A1 WO9408596 A1 WO 9408596A1
Authority
WO
WIPO (PCT)
Prior art keywords
container according
solution
block copolymer
molecular weight
daltons
Prior art date
Application number
PCT/GB1993/002141
Other languages
English (en)
French (fr)
Inventor
Mary Sou
Craig William Davis
Alison Green Floyd
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Priority to AU52842/93A priority Critical patent/AU674895B2/en
Priority to KR1019950701458A priority patent/KR950703345A/ko
Priority to SK447-95A priority patent/SK44795A3/sk
Priority to JP6509782A priority patent/JPH08502284A/ja
Priority to BR9307268A priority patent/BR9307268A/pt
Priority to PL93308459A priority patent/PL308459A1/xx
Priority to EP93923008A priority patent/EP0671919A1/en
Publication of WO1994008596A1 publication Critical patent/WO1994008596A1/en
Priority to NO951462A priority patent/NO951462L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes

Definitions

  • the present invention relates to a stable pharmaceutical formulation of a polyoxypropylene/polyoxyethylene block copolymer.
  • Certain surface-active polyoxypropylene/polyoxyethylene block copolymers have been found to have beneficial effects in animal and human medicine.
  • the copolymers may be used for treating circulatory disorders alone or in combination with other agents, such as fibrinolytic enzymes, anticoagulants, free radical scavengers, anti- inflammatory agents, antibiotics, membrane stabilisers and/or perfusion media. These uses are described in US Patent Nos.
  • the surface-active copolymers are effective in circulatory disorders where there is a pathological hydrophobic interaction between cells and/or molecules. These interactions are believed to be caused by 1) a higher than normal concentration of fibrinogen, 2) generation of intravascular or local soluble fibrin, especially high molecular weight fibrin, 3) increased friction in the microvasculature, or 4) mechanical or chemical trauma to blood components. These disorders cause an increase in pathological hydrophobic interactions of blood components such as cells and molecules. It is believed that fibrin, especially soluble fibrin, increases adhesion of cells to one another, markedly increases friction in small blood vessels, and increases viscosity of the blood especially at low shear rates. The effects of the surface-active copolymers are believed to be essentially lubrication effects because they reduce the friction caused by the adhesion.
  • antioxidants Commercially available surface-active polyoxypropylene/polyoxyethylene block copolymers generally contain antioxidants .
  • poloxamer 188 that may be purchased from BASF (Parsippany, New Jersey, U.S.A.) contains BHT (butylated hydroxytoluene).
  • BHT butylated hydroxytoluene
  • This antioxidant is not standardised for pharmaceutical use.
  • antioxidants tend to be hydrophobic and insoluble in aqueous medium, and some may also present toxicity problems. This is clearly undesirable in an injectable solution for use in medicine. It is therefore an object of the present invention to provide an aqueous solution of a block copolymer that is substantially free of such antioxidants.
  • EP-A- 103290 describes aqueous pharmaceutical formulations of polyoxypropylene and polyoxyethylene adjusted to a physiologically acceptable pH. preferably from 6 to 8, by addition of electrolytes and buffers. It does not however describe a pharmaceutical formulation of a block copolymer of polyoxypropylene/polyoxyethylene and does not describe or allude to any of the above-mentioned disadvantages associated with such a polymer.
  • US Patent No. 4,938,961 describes an aqueous solution of polypropylene glycol but makes no reference to solutions of a block copolymer of polyoxypropylene/polyoxyethylene.
  • the present invention accordingly provides a sealed pharmaceutically acceptable container which contains in a vacuum or in an inert atmosphere a sterile aqueous injectable solution of a block copolymer of formula (I):
  • a is an integer such that the hydrophobe represented by (C ⁇ H O) has a
  • the solution being substantially free from an antioxidant and being buffered at a pH from 5.5 to 6.5.
  • a preferred block copolymer of formula (I) is wherein the molecular weight of the hydrophobe (C H O) is approximately 1750 Daltons and the total molecular weight of
  • the copolymer is approximately 8400 Daltons.
  • a particular example of such a block copolymer is that which is referred to as poloxamer 188 (BASF, Parsippany, New Jersey,
  • poloxamer 188 Commercially available sources of poloxamer 188 are stated to have a molecular weight of approximately 8400 Daltons. In reality, the block copolymer is composed of molecules having a molecular weight from less than 3000 Daltons to over 20,000 Daltons. The molecular diversity and distribution of molecules of commercial poloxamer 188 can be illustrated by broad primary and secondary peaks detected using gel permeation chromatography, as described in WO 92/16484.
  • the high molecular weight components i.e. the components having a molecular weight greater than 15kDaltons, that are present in commercially available poloxamer 188 normally amount to 3%, by weight, of the block copolymer or even more. Such significant amounts may give rise to unwanted side-effects in the clinical application of the block copolymer. In particular, these components have a longer elimination phase half life than the bulk of the block copolymer and thus accumulate in the plasma and kidneys. In addition, these high molecular weight components may be responsible for activation of the complement system. It is thus preferred that the block copolymer of use with the present invention is free, at least to a substantial extent, i.e. less than 1%, preferably 0.5% or 0.2%, by weight, of any molecules having a molecular weight greater than 15kDaltons.
  • a standard measure of the molecular weight distribution of a polymer is its polydispersity. This is referred to and described in WO92/16484, the contents of which are incorporated herein by reference. Briefly, a polydispersity of 1.0 is indicative of a polymer in which all molecules have the same molecular weight. A typical polymer may have a polydispersity of 2 to 5.
  • the block copolymer of polyoxypropylene/ polyoxyethylene of use with the present invention preferably has a polydispersity less than 1.4, preferably 1.3 or 1.2 or even 1.1.
  • the surface-active block copolymer may be formed by condensation of ethylene oxide and propylene oxide at elevated temperature and pressure in the presence of a basic catalyst.
  • a basic catalyst there is statistical variation in the number of monomer units which combine to form a polymer chain in each copolymer.
  • the molecular weights given are approximations of the average weight of copolymer molecule in each preparation. A more detailed discussion of the preparation of these copolymers is found in U.S. Patent No. 2,674,619, which is incorporated herein by reference.
  • block copolymer that is the forms which are free from any significant amount of molecules having a molecular weight greater than 15kDaltons, or which have a polydispersity of less than 1.4, may be obtained by the process described in WO 92/16484.
  • block copolymers such as poloxamer 188
  • the antioxidant should be removed from the copolymer, for example, by filtration or by some other means known in the art.
  • the block copolymer is obtained in a form that is already substantially free from an antioxidant.
  • the amount of block copolymer contained within the aqueous injectable solution is preferably from 135 to 165 mg/mL, especially about 150 -mg mL (i.e. milligrams per millilitre).
  • the pH of the aqueous injectable solution is preferably about 6.
  • the aqueous injectable solution is buffered at the desired pH using a buffering agent.
  • buffering agents include citrate (for example sodium citrate/citric acid).
  • concentration of the buffering agent, in particular citrate buffering agent should preferably be from 0.005 to 0.05M, particularly about 0.01M.
  • the medium for the aqueous injectable solution is wholly or substantially aqueous.
  • the aqueous injectable solution is preferably of such tonicity with the blood serum of the patient so as to avoid undesirable side effects. If the tonicity of the aqueous injectable solution needs to be increased, then a substantially isotonic solution may be obtained by the inclusion of a pharmaceutically acceptable agent that is capable of raising the tonicity of the solution to the required level. Examples of such an agent are well known in the art and include dextrose and sodium chloride and mixtures thereof.
  • the aqueous injectable solution may be provided in sterile form by filtration or by autoclaving.
  • the formulation of the aqueous injectable solution and its filling into a pharmaceutically acceptable containers are preferably carried out in accordance with procedures known in the art in which conditions are designed to minimise the oxygen in the formulation solution or headspace.
  • Examples of a pharmaceutically acceptable container include plastic and glass containers, such as vials, ampoules and bottles.
  • the containers may optionally be coloured, such as amber, to reduce the exposure of the aqueous injectable solution to UN light and possible degradation.
  • the containers may be colourless but packaged in opaque cartons.
  • the aqueous injectable solution is contained in an inert atmosphere which is nitrogen.
  • the surface-active copolymer may be used in the treatment of circulatory disorders which are caused by or which cause pathological hydrophobic interaction of blood components.
  • diseases include myocardial infarction, stroke, bowel or other tissue infarctions, malignancies, adult respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), diabetes, unstable angina pectoris, hemolytic uremic syndrome, red cell fragmentation syndrome, heat stroke, retained fetus, eclampsia, malignant hypertension, sickle cell disease, burns, crush injuries, fractures, trauma producing shock, major surgery, sepsis, bacterial, parasitic, viral and rickettsial infections which promote activation of the coagulation system, central nervous system trauma, and during and immediately after any major surgery.
  • ARDS adult respiratory distress syndrome
  • DIC disseminated intravascular coagulation
  • diabetes unstable angina pectoris
  • hemolytic uremic syndrome red cell fragmentation syndrome
  • heat stroke retained fetus
  • the surface-active copolymer is also effective in increasing the collateral circulation to undamaged tissues with compromised blood supply. Such tissues are frequently adjacent to areas of vascular occlusion. The mechanism appears to be reducing pathological hydrophobic interactions in small blood vessels. Circulatory disorders in which the surface-active copolymers are effective include cerebral thrombosis, cerebral embolus, myocardial infarction, unstable angina pectoris, transient cerebral ischemic attacks, intermittent claudication of the legs, plastic and reconstructive surgery, balloon angioplasty, peripheral vascular surgery, and orthopedic surgery, especially when using a tourniquet.
  • the copolymer may also be used for the preservation of organs for transplantation.
  • the aqueous injectable solution of the block copolymer may be administered to the patient by bolus injection or preferably by infusion.
  • a convenient site for administration will normally be a peripheral vein.
  • a bolus injection usually comprises administration over a two minute period.
  • Infusions are normally carried out with the solution contained within an infusion bag or bottle or within an electrically operated infusion pump. The solution may be delivered from the infusion bag or bottle to the patient by gravity feed or by the use of the infusion pump.
  • an effective amount of the block copolymer to treat a patient with a circulatory disorder will of course depend on a number of factors including, for example, the age and weight of the patient, the precise condition requiring treatment, the route of administration, and will ultimately be at the discretion of the attendant physician. It is likely however that an effective amount will generally be in the range of from 0.2 to 3.0 g kg, preferably 1.5 to 2.5 g/kg bodyweight, administered to a patient over a period from 1 to 48 hours.
  • aqueous injectable solution provided in this way is a clear, colourless solution, free of particulate matter, haze or swirl and is stable, as evidenced by the following data:
  • Fluor Fluoroscent met: methanol l.s.: labelled strength form: formaldehyde
  • Example 1 The procedure of Example 1 was repeated for a 200 litre batch size using the following formulation and collecting 160 litres in vessel No.1 and 40 litres in vessel No.2 : Poloxamer 188, NF 1 30.00 kg
  • the resulting aqueous injectable solution was similar in physical appearance as that provided by Example 1.
  • the following stability data were obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Packages (AREA)
PCT/GB1993/002141 1992-10-19 1993-10-18 Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it WO1994008596A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU52842/93A AU674895B2 (en) 1992-10-19 1993-10-18 Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it
KR1019950701458A KR950703345A (ko) 1992-10-19 1993-10-18 폴리옥시에틸렌-폴리옥시프로필렌 블록 공중합체가 주성분인 조성물 및 그것을 함유하는 컨테이너(composition based on polyoxyethylene-polyoxypropylene block copolymers and container contaning it)
SK447-95A SK44795A3 (en) 1992-10-19 1993-10-18 Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it
JP6509782A JPH08502284A (ja) 1992-10-19 1993-10-18 ポリオキシエチレン・ポリオキシプロピレンブロックコポリマーに基づく組成物及びそれを収容する容器
BR9307268A BR9307268A (pt) 1992-10-19 1993-10-18 Recipiente selado farmaceuticamente aceitável
PL93308459A PL308459A1 (en) 1992-10-19 1993-10-18 Polyoxyethylene/polyoxypropylene block copolymer based composition and container holding such composition
EP93923008A EP0671919A1 (en) 1992-10-19 1993-10-18 Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it
NO951462A NO951462L (no) 1992-10-19 1995-04-18 Preparat basert på polyoksyetylen-polyoksypropylenblokk kopolymerer og beholder som inneholder preparatet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9221883.3 1992-10-19
GB929221883A GB9221883D0 (en) 1992-10-19 1992-10-19 Novel formulation

Publications (1)

Publication Number Publication Date
WO1994008596A1 true WO1994008596A1 (en) 1994-04-28

Family

ID=10723654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/002141 WO1994008596A1 (en) 1992-10-19 1993-10-18 Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it

Country Status (19)

Country Link
EP (1) EP0671919A1 (enrdf_load_html_response)
JP (1) JPH08502284A (enrdf_load_html_response)
KR (1) KR950703345A (enrdf_load_html_response)
AU (1) AU674895B2 (enrdf_load_html_response)
BR (1) BR9307268A (enrdf_load_html_response)
CA (1) CA2147889A1 (enrdf_load_html_response)
CZ (1) CZ63395A3 (enrdf_load_html_response)
GB (1) GB9221883D0 (enrdf_load_html_response)
HU (1) HUT75701A (enrdf_load_html_response)
IL (1) IL107313A0 (enrdf_load_html_response)
MX (1) MX9306467A (enrdf_load_html_response)
NO (1) NO951462L (enrdf_load_html_response)
NZ (1) NZ256890A (enrdf_load_html_response)
PL (1) PL308459A1 (enrdf_load_html_response)
SI (1) SI9300545A (enrdf_load_html_response)
SK (1) SK44795A3 (enrdf_load_html_response)
TW (1) TW276183B (enrdf_load_html_response)
WO (1) WO1994008596A1 (enrdf_load_html_response)
ZA (1) ZA937714B (enrdf_load_html_response)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185162A4 (en) * 2007-08-10 2012-04-25 Synthrx Inc POLYMER THERAPY FOR THE TREATMENT OF CHRONIC MICROVASCULAR DISEASES
WO2015058013A1 (en) 2013-10-16 2015-04-23 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
WO2016007537A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432511A (zh) * 2018-12-29 2019-03-08 常州乐奥医疗科技股份有限公司 一种温敏型水凝胶及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
EP0103290A2 (de) * 1982-09-14 1984-03-21 Intermedicat Gmbh Pharmazeutische Zubereitungen zur Behandlung von unerwünschten Verwachsungen sowie deren Verwendung
US4938961A (en) * 1989-04-28 1990-07-03 Geoffrey Collins Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia
WO1990007336A1 (en) * 1988-12-29 1990-07-12 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
EP0103290A2 (de) * 1982-09-14 1984-03-21 Intermedicat Gmbh Pharmazeutische Zubereitungen zur Behandlung von unerwünschten Verwachsungen sowie deren Verwendung
WO1990007336A1 (en) * 1988-12-29 1990-07-12 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US4938961A (en) * 1989-04-28 1990-07-03 Geoffrey Collins Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185162A4 (en) * 2007-08-10 2012-04-25 Synthrx Inc POLYMER THERAPY FOR THE TREATMENT OF CHRONIC MICROVASCULAR DISEASES
WO2015058013A1 (en) 2013-10-16 2015-04-23 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
WO2016007537A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US9403941B2 (en) 2014-07-07 2016-08-02 Mast Therapeutics, Inc. Poloxamer composition free of long circulating material and methods for production and uses thereof
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
US10501577B2 (en) 2014-07-07 2019-12-10 Liferaft Biosciences, Inc. Poloxamer composition free of long circulating material and methods for production and uses thereof
EP3747448A1 (en) 2014-07-07 2020-12-09 LifeRaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
US11155679B2 (en) 2014-07-07 2021-10-26 Liferaft Biosciences, Inc. Poloxamer composition free of long circulating material and methods for production and uses thereof

Also Published As

Publication number Publication date
JPH08502284A (ja) 1996-03-12
MX9306467A (es) 1994-05-31
TW276183B (enrdf_load_html_response) 1996-05-21
NO951462L (no) 1995-06-13
SK44795A3 (en) 1996-05-08
BR9307268A (pt) 1999-05-11
PL308459A1 (en) 1995-07-24
EP0671919A1 (en) 1995-09-20
NZ256890A (en) 1995-10-26
CA2147889A1 (en) 1994-04-28
GB9221883D0 (en) 1992-12-02
SI9300545A (en) 1994-06-30
NO951462D0 (no) 1995-04-18
KR950703345A (ko) 1995-09-20
IL107313A0 (en) 1994-01-25
ZA937714B (en) 1995-04-18
AU5284293A (en) 1994-05-09
AU674895B2 (en) 1997-01-16
HU9501104D0 (en) 1995-06-28
CZ63395A3 (en) 1995-07-12
HUT75701A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
US5696298A (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5990241A (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
KR100884711B1 (ko) 외용 투여용 올로파타딘 제제
KR100191873B1 (ko) 안정화된 pvp-i 용액
IE83219B1 (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US20030203876A1 (en) Organic compounds
US20030108610A1 (en) Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
EP1259226B1 (en) Anaesthetic formulations
EP0095897A2 (en) Pharmaceutical formulations
US6436425B1 (en) Method and non-gelling composition for inhibiting post-surgical adhesions
US6683100B2 (en) Organic compounds
AU708688B2 (en) Composition comprising mupirocin and chlorhexidine
US6399624B1 (en) Method and composition for inhibiting post-surgical adhesions
WO1994008596A1 (en) Composition based on polyoxyethylene-polyoxypropylene block copolymers and container containing it
KR100760326B1 (ko) 카르밤아제핀 또는 그의 유도체를 포함하는 비경구 제형
WO1998029127A1 (en) Method and non-gelling composition for inhibiting post-surgical adhesions
WO2017149552A1 (en) Parenteral dosage form of amiodarone
EP1800664B1 (en) Pharmaceutical formulations for parenteral administration comprising epothilone
HK1105808A1 (en) Pharmaceutical formulations for parenteral administration comprising epothilone
HK1105808B (en) Pharmaceutical formulations for parenteral administration comprising epothilone
MXPA00003413A (en) Parenteral formulations comprising carbamazepine or its derivatives
HK1116419A (en) Multi-dose erythropoietin formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CZ HU JP KR KZ NO NZ PL RU SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PV1995-633

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 44795

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2147889

Country of ref document: CA

Ref document number: 1993923008

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 416861

Country of ref document: US

Date of ref document: 19950417

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 256890

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: PV1995-633

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1993923008

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1995-633

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1993923008

Country of ref document: EP